Emergent Biosolutions Gross Profit

Emergent Biosolutions (EBS) currently reports a gross profit of $18M as of June 2026. That compares with $520M in the prior-year period — down 96.5% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Emergent Biosolutions's gross profit history and peer comparisons.

Emergent Biosolutions's gross profit decreased from $520M to $18M — a 96.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Emergent Biosolutions's gross profit of $18M is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Emergent Biosolutions reported $18M in gross profit as of June 2026. That compares with $520M in the prior-year period — down 96.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Emergent Biosolutions, and consider following EBS for alerts when major investors trade the stock.